Green Thumb Industries (GTBIF) Income from Continuing Operations (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Income from Continuing Operations came in at 15047000.0 in Q1 2026, up 79.11% YoY from 8401000.0 in Q1 2025, and down 93.04% on a QoQ basis from 216267000.0 in Q4 2025.
Green Thumb Industries (GTBIF) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Income from Continuing Operations data on file, last reported at 15047000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 79.11% year-over-year to 15047000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 255847000.0 (up 63.51% YoY) and the FY2025 annual result came in at 249201000.0, up 38.89% from the prior year.
- Income from Continuing Operations retreated to 15047000.0 in Q1 2026, from 216267000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 216267000.0 in Q4 2025 to a low of 98994000.0 in Q4 2022.
- A 5-year average of 31324647.06 and a median of 15047000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 166.62% — and 2024, when it surged 233.31%.
- Tracing GTBIF's Income from Continuing Operations over 5 years: stood at 98994000.0 in 2022, then jumped by 190.29% to 89377000.0 in 2023, then surged by 32.44% to 118374000.0 in 2024, then surged by 82.7% to 216267000.0 in 2025, then plunged by 93.04% to 15047000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 15047000.0 (Q1 2026), 216267000.0 (Q4 2025), and 23801000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Green Thumb Industries | 1.69 Bn | 1.41 Bn | 137.87 Mn | 3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.43 Mn |
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 216.27 Mn |
| Sep 30, 2025 | 23.80 Mn |
| Jun 30, 2025 | 732,000.00 |
| Mar 31, 2025 | 8.40 Mn |
| Dec 31, 2024 | 118.37 Mn |
| Sep 30, 2024 | 8.78 Mn |
| Jun 30, 2024 | 20.92 Mn |
| Mar 31, 2024 | 31.35 Mn |
| Dec 31, 2023 | 89.38 Mn |
| Sep 30, 2023 | 10.81 Mn |
| Jun 30, 2023 | 13.69 Mn |
| Mar 31, 2023 | 9.41 Mn |
| Dec 31, 2022 | -98.99 Mn |
| Sep 30, 2022 | 10.15 Mn |
| Jun 30, 2022 | 24.73 Mn |
| Mar 31, 2022 | 29.69 Mn |
| Dec 31, 2021 | 148.61 Mn |
| Sep 30, 2021 | 21.59 Mn |